KRAS and neoplasm: The combination of cetuximab and sotorasib effectively inhibited the activation of the EGFR-driven MAPK pathway in CRC cells, thus sustaining downstream target inhibition, significantly improving KRAS G12C inhibition, and achieving tumour regression.